Supplementary Data from The Cytochrome P450 Slow Metabolizers CYP2C9*2 and CYP2C9*3 Directly Regulate Tumorigenesis via Reduced Epoxyeicosatrienoic Acid Production

This file contains the primer sequence of CYP2C9* variants (Supplementary Table S1); the SNPs genotyped in the BioVU NSCLC study (Supplementary Table S2); quality control measures of SNPs in the BioVU NSCLC study (Supplementary Table S3); clinical and demographic description of NSCLC cases (Supplementary Table S4); the association of clinical and demographic variables with survival (Supplementary Table S5); the genotypes in the NSCLC cases (Supplementary Table S6); the spectra of CYP2C9* variants and the effect of arachidonic acid on CYP2C9* variant (Supplementary Figure S1); the association between CYP2C9* variants and platinum chemotherapy (Supplementary Figure S2).